306
- Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P,
Calabrò R. Carvedilol increases two-year survival in dialysis patients with dilated cardiomy-
opathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–44. - Brown KE, Dhaun N, Goddard J, Webb DJ. Potential therapeutic role of phosphodiesterase
type 5 inhibition in hypertension and chronic kidney disease. Hypertension. 2014;63(1):
5–11. - Grover-Páez F, Villegas Rivera G, Guillén OR. Sildenafil citrate diminishes microalbuminuria
and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract.
2007;78(1):136–40. - Brochu E, Lacasse S, Larivière R, Kingma I, Grose JH, Lebel M. Differential effects of endo-
thelin- 1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc
Nephrol. 1999;10(7):1440–6. - Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb
DJ. Endothelin-a receptor antagonism reduces blood pressure and increases renal blood flow
in hypertensive patients with chronic renal failure: a comparison of selective and combined
endothelin receptor blockade. Circulation. 2004;109(9):1186–93. - Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T. Mitchell a; SPP301
(Avosentan) Endothelin antagonist evaluation in diabetic nephropathy study investigators.
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol.
2009 Mar;20(3):655–64. - Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. Addition of
atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
J Am Soc Nephrol. 2011 Apr;22(4):763–72.
L. Segall